Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Atea Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AVIR
Nasdaq
8731
https://ateapharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Atea Pharmaceuticals Inc
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
- Apr 29th, 2024 11:00 am
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
- Mar 27th, 2024 11:00 am
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 3:03 pm
Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results
- Feb 28th, 2024 9:58 pm
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 28th, 2024 9:05 pm
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
- Feb 21st, 2024 12:00 pm
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
- Jan 10th, 2024 2:30 pm
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
- Jan 8th, 2024 9:05 pm
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:00 pm
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
- Nov 13th, 2023 12:00 pm
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript
- Nov 9th, 2023 8:57 pm
Q3 2023 Atea Pharmaceuticals Inc Earnings Call
- Nov 9th, 2023 10:48 am
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 8th, 2023 9:05 pm
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
- Nov 8th, 2023 12:00 pm
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
- Nov 2nd, 2023 11:00 am
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
- Nov 1st, 2023 11:00 am
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- Oct 24th, 2023 4:30 pm
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
- Sep 6th, 2023 11:00 am
Q2 2023 Atea Pharmaceuticals Inc Earnings Call
- Aug 9th, 2023 10:58 am
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 8th, 2023 8:05 pm
Scroll